NovaBay Pharma Announces Leadership Changes and Reverse Stock Split
I'm PortAI, I can summarize articles.
NovaBay Pharma announced leadership changes and a reverse stock split during its Annual Meeting of Stockholders on October 16, 2025. The stockholders approved a reverse stock split to reduce outstanding shares, affecting voting rights and future issuances. Michael Kazley was appointed as the new CEO and Chairman, while several board members resigned. The company filed to increase its authorized shares, but a proposal to increase preferred stock was rejected. Analysts rate NBY stock as a Hold with a $1.50 price target, reflecting financial challenges despite some positive corporate events.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments